DE:1RT Stock Latest News
Company AnnouncementsNuformix boosts NXP002 case with new TGF-β pathway data2w ago
Company AnnouncementsNuformix appoints Tim Metcalfe as new chairman to drive strategic value2M ago
Company AnnouncementsNuformix Advances Inhaled Fibrosis Drug NXP002 With Positive Preclinical Data2M ago
Company AnnouncementsNuformix Secures Orphan Status and Funding to Advance Inhaled IPF Therapy5M ago
Company AnnouncementsNuformix updates market on enlarged share capital and voting rights7M ago
Company AnnouncementsNuformix Raises £1m to Accelerate NXP002 Fibrosis Programme7M ago- Company AnnouncementsNuformix Posts 2025 Annual Report and Sets Date for 2026 AGM9M ago
Company AnnouncementsNuformix Sharpens Focus on Partnering Lead IPF Drug NXP002 as Preclinical Data Strengthen Case9M ago
Company AnnouncementsNuformix PLC Updates Total Voting Rights Following New Share Issuance11M ago
Company AnnouncementsNuformix Awaits FDA Response on Orphan Drug Designation for IPF Treatment11M ago
Company AnnouncementsNuformix plc Successfully Completes Oversubscribed Open Offer11M agoCompany AnnouncementsNuformix Launches £228,081 Open Offer to Advance Drug Repurposing Initiatives1y ago
- Company AnnouncementsNuformix to Present NXP002 Insights at European Respiratory Congress1y ago
- Company AnnouncementsNuformix Seeks US FDA Orphan Drug Designation for NXP002 in IPF1y ago
Company AnnouncementsNuformix Confirms Total Voting Rights Following Share Issuance1y ago- Company AnnouncementsNuformix Secures European Orphan Drug Designation for NXP002 in IPF1y ago
Company AnnouncementsNuformix plc Announces Prospectus for New Share Issuance1y agoCompany AnnouncementsNuformix Announces £210,000 Placing to Advance Fibrosis Treatment Program1y ago